Peptides are chains of amino acids, which are the building blocks of proteins that are essential for the skin. In addition to being naturally produced by the body, peptides are also used in topical ...

Peptides for hair growth are having a moment, much like their skin-care counterparts, which have become a beauty mainstay. When applied to the scalp, these ingredients can help hydrate, prevent ...

Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China Department of Nuclear Medicine, Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai ...

Collagen peptides are a popular supplement often mixed in with drinks or smoothies or included in foods like protein bars. Collagen is the main protein in the body. It is a major structural protein in ...

Table 01: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Product Type, 2020-2035 Table 02: Global Peptide Therapeutics Market Value (US$ Mn) Forecast, by Application, 2020-2035 Table ...

Merck & Co – known as MSD outside of the US and Canada – and Cyprumed have entered into a partnership aimed at developing oral formulations of Merck’s peptides, with the deal worth over $493m. The ...

Last week, Merck entered into a non-exclusive license and option agreement with Cyprumed GmbH, aiming to enhance its peptide offerings through innovative oral delivery technology. Despite this ...

Additionally, zeocin resistant cells were screened for positive insertion of the coding DNA for the hybrid peptide FowlTα1 utilizing PCR and DNA sequencing (Sanger Sequencing, BGI Genomics, Beijing, ...

Mer­ck is look­ing for ways to make its drugs eas­i­er to ad­min­is­ter. The large phar­ma is li­cens­ing a drug de­liv­ery plat­form from Aus­tri­an biotech Cyprumed … ...

Cyprumed may receive up to $493 million in milestone payments from Merck for peptide drug delivery tech. Merck’s pipeline includes Phase 3 PCSK9 inhibitor and GLP-1/glucagon receptor agonist.

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.